CD532 |
| Catalog No.GC48982 |
CD532 est un puissant inhibiteur de la kinase Aurora A avec une IC50 de 45 nM. CD532 a le double effet de bloquer l'activité de la kinase Aurora A et de conduire la dégradation de MYCN. CD532 peut également interagir directement avec AURKA et induit un changement conformationnel global. Le CD532 peut être utilisé pour la recherche sur le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1639009-81-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CD532 is an inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase.1 It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM.2 CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM).1 It prevents S-phase entry in SK-N-BE(2) cells when used at a concentration of 1 µM.1 CD532 (25 mg/kg) reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model.
1.Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., et al.Drugging MYCN through an allosteric transition in Aurora kinase ACancer Cell26(3)414-427(2014) 2.Lee, J.K., Phillips, J.W., Smith, B.A., et al.N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cellsCancer Cell29(4)536-547(2016)
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *